In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year.

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?